Presentation of Earnings Conference Call pertaining to the Audited Financial Results for the quarter and year ended March 31, 2026
PIIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
PI Industries reported Q4 FY26 revenue of ₹15,652 Mn (down 12% YoY) and full-year FY26 revenue of ₹67,137 Mn (down 16% YoY). EBITDA for FY26 stood at ₹17,053 Mn with 25% margin, matching guidance. Agchem exports declined ~15% due to global agrochemical contraction, while domestic revenue softened ~9% YoY. However, Pharma revenue grew 40% YoY to ₹3,005 Mn, contributing ~6% of exports. The company commercialized 5 new molecules in exports and 4 products in domestic markets during FY26. Management guided cautious optimism for FY27 with 5+ new molecule launches and strong order book support. Balance sheet remains strong with ₹34,265 Mn surplus cash (debt-free).
The stock faces near-term pressure from cyclical agrochemical downturn but management's margin discipline, new product pipeline, and diversification into pharma position it well for recovery in FY27 with EBITDA margin guidance maintained at 25%.